GlassScriptPhysician profile
Alivia R Parker
NPI 1124797113
$6,284.05
in general payments reported to CMS, 2019-2025
22 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $848 · 2023: $1,275 · 2024: $1,354 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.56 |
| Education | $156.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,402.77 | 2022-2025 | |
| Alkermes, INC. | $718.39 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $645.46 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $603.37 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $590.96 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $524.80 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $342.30 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $334.59 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $308.97 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $241.90 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $112.98 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $103.61 | 2021-2022 | |
| Indivior INC. | $65.79 | 2022-2024 | Perseris |
| Braeburn INC. | $62.21 | 2023-2024 | Brixadi |
| Bausch Health US, LLC | $61.07 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.36 | 2022 | |
| Supernus Pharmaceuticals, INC. | $34.38 | 2024-2025 | Qelbree |
| Jazz Pharmaceuticals INC. | $26.65 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.76 | 2025 | |
| Lundbeck LLC | $15.01 | 2024 | Rexulti |
| Orexo US, INC. | $14.39 | 2023 | Zubsolv |
| Almatica Pharma LLC | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alivia Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.